FDA warned ImmunityBio that a TV ad and its chief scientist’s podcast comments created a misleading impression that Anktiva “can cure and even prevent all cancer,” and the company’s market value fell by more than 20% Tuesday. The letter targets promotion of Anktiva (nogapendekin alfa inbakicept-pmln), an IL-15 agonist approved in 2024 with BCG for BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (± papillary tumors).

Why It Matters To Oncology

• Regulators are drawing a bright line between an oncology drug’s labeled setting (NMIBC) and broad “cure/prevent cancer” narratives—especially when delivered via mass media and podcasts.

• For drug discovery and development teams, the episode underscores how mechanism-forward enthusiasm (e.g., cytokine agonism) can be interpreted as efficacy claims if not tightly scoped to evidence and indication.

• For Bladder Cancer clinicians, it’s a reminder that Anktiva’s benefit-risk discussion should stay anchored to the approved NMIBC + BCG context, not pan-cancer extrapolations.

The Financials

• The FDA action shaved more than 20% off ImmunityBio’s valuation Tuesday.

• The agency is requesting a response within 15 days detailing a plan to discontinue the communications or cease distribution of Anktiva.

What They're Saying

• FDA: The ad and remarks created “a misleading impression that Anktiva…can cure and even prevent all cancer.”

• ImmunityBio’s Global Chief Scientific and Medical Officer Patrick Soon-Shiong made the cited comments on The Sean Spicer Show.

What's Next

• Watch for ImmunityBio’s corrective actions (retractions, revised promotional materials, field guidance) and whether the company narrows external messaging to the approved NMIBC label.

• Monitor for downstream impacts on commercial execution in urologic oncology and on future label-expansion strategy, where promotional boundaries are typically scrutinized most closely.